- Global Pharma News & Resources

Press Releases - 2019-01-10

Date Title Company
10-Jan-2019 ACI Specialty Benefits Appoints Thomas Kellerhouse as Managing Director ACI Specialty Benefits
10-Jan-2019 The global intelligent asthma monitoring devices market was valued at $20 million in 2017, and is expected to reach $655 million by 2025, registering a CAGR of 54.5% from 2018 to 2025 ReportBuyer
10-Jan-2019 Innovative PT Opens New Baltimore City Physical Therapy Clinic The Growth Coach of Greater Baltimore
10-Jan-2019 Global Network Expansion Accelerates Under Leadership of Pelican BioThermal's Vice President of Credo™ on Demand Pelican BioThermal
10-Jan-2019 Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Ocular Therapeutix
10-Jan-2019 Tilray, Inc. to Present at the 2019 ICR Conference Tilray, Inc.
10-Jan-2019 Fellow Health Partners Expands New York Client Base; Brooklyn Surgery Center outsources all billing to Fellow Health Partners, allowing them to focus 100% on patient care Fellow Health Partners, Inc.
10-Jan-2019 Mindray Announces New A-Series Advantage Anesthesia Delivery Platform Mindray
10-Jan-2019 GoGreen Hemp Launches Cellulose Tencel CBD Infused Face Mask GoGreen Hemp
10-Jan-2019 Oasis Recovery Centers Opens New Office at Hope for New Hampshire Recovery Oasis Recovery Centers
10-Jan-2019 New CEO Takes Helm at Austin-based Karis The Karis Group
10-Jan-2019 Foremost Medical Equipment and One Beat CPR Learning Center Inc to Become One Beat CPR Learning Center LLC One Beat CPR Learning Center Inc
10-Jan-2019 SpineSource® Acquires French Medical Device Technology SpineSource, Inc.
10-Jan-2019 Hydrofarm Announces Strategic Partnership with Argus Controls for Advanced Horticultural Production Hydrofarm Holdings Group, Inc.
10-Jan-2019 New AI ‘shapeshift’ test identifies women with ‘very high risk’ ovarian cancer The Institute of Cancer Research
10-Jan-2019 Johnson Matthey partners with Immunomedics to develop life- saving cancer treatment. Immunomedics
10-Jan-2019 HVIVO reports that the Phase IIb viral challenge Study for FLU-v (FLU-v004) achieved the primary endpoint of a statistically significant reduction in Mild to Moderate Influenza HVIVO
10-Jan-2019 Invitrocue announces Board Changes Invitrocue
10-Jan-2019 Novartis response to NICE Appraisal Consultation Document (ACD) for Aimovig® (erenumab) for the prevention of migraine Novartis